A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants
NCT06895356 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 83
Last updated 2025-06-26
Summary
This study will assess the relative bioavailability of two different Oral formulations of tavapadon in healthy adult participants.
Conditions
- Healthy Volunteer
Interventions
- DRUG
-
Tavapadon
Oral: Tablet
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
ABBVIE INC. · AbbVie
Study Design
- Allocation
- RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2025-03-26
- Primary Completion
- 2025-06-16
- Completion
- 2025-06-16
Countries
- United States
Study Locations
More Related Trials
-
A Study in Healthy People to Compare 2 Different Formulations of BI 1358894 Tablets Taken With or Without Food
NCT05155306 ·Status: COMPLETED ·Phase: PHASE1
-
A Crossover Study to Evaluate Relative Bioavailability of Two JNJ-54781532 Tablet Formulations in Healthy Adult Participants
NCT02117505 ·Status: COMPLETED ·Phase: PHASE1
-
Bioavailability and Pharmacokinetics of BI 135585 XX Administered as Tablet With and Without Food
NCT01286571 ·Status: COMPLETED ·Phase: PHASE1
-
Bioavailability of BI 1356 After Single Oral Administration Given as Different Tablet Formulation in Healthy Male Volunteers
NCT02183363 ·Status: COMPLETED ·Phase: PHASE1
-
Bioavailability of BI 1356 After Co-administration With Ritonavir Compared to the Bioavailability of BI 1356 Alone in Healthy Male Volunteers
NCT02183441 ·Status: COMPLETED ·Phase: PHASE1
-
Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BS
NCT02180503 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Compare the Oral Bioavailability of Single Doses of Two Vapendavir Drug Formulations in Healthy Volunteers
NCT02101866 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of the Bioavailability of Two ABT-072 Tablet Formulations as Compared to ABT-072 Capsule Formulation
NCT00947440 ·Status: COMPLETED ·Phase: PHASE1
-
Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation
NCT05263895 ·Status: COMPLETED ·Phase: PHASE1
-
A Bioavailability and Pharmacokinetic Study of Subcutaneous and Intravenous RO6811135 in Healthy Volunteers
NCT01802853 ·Status: COMPLETED ·Phase: PHASE1
-
Lesinurad Tablet Relative Bioavailability
NCT01986556 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics and Bioavailability Comparison of Two Different Formulations of MNTX Tablets
NCT01366352 ·Status: COMPLETED ·Phase: PHASE1
-
Relative Bioavailability of Two Newly Developed Tablet Formulations (TF2 and iFF)Compared to BI 1060469 TF1 Formulation, Following Oral Administration (Low and High Dose)in Healthy Female Subjects
NCT02438696 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants
NCT06477926 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Compare Two Tablet Forms of Tafamidis in Healthy Participants
NCT05482308 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Relative Bioavailability of Immediate Release Formulations of ABBV-903 in Healthy Adult Participants
NCT05836506 ·Status: COMPLETED ·Phase: PHASE1
-
Relative Bioavailability, Safety and Tolerability of Two Tablet Formulations of BIIL 284 BS
NCT02265666 ·Status: COMPLETED ·Phase: PHASE1
-
A Study in Healthy People to Compare 2 Different Formulations of BI 1015550 Taken With or Without Food
NCT05428436 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects
NCT02034565 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Participants
NCT04696393 ·Status: COMPLETED ·Phase: PHASE1
-
Study To Assess The Pharmacokinetics Of 2 Different Formulations Of PF-04991532
NCT01388829 ·Status: COMPLETED ·Phase: PHASE1
-
Relative Bioavailability of a BI 187004 Tablet Formulation in Comparison With an Oral Solution and the Influence of Food on the Tablet Formulation in Healthy Volunteers
NCT02161432 ·Status: COMPLETED ·Phase: PHASE1
-
Investigation of the Metabolism and Pharmacokinetics of 10 mg [14C] BI 1356 Administered Orally Compared to 5 mg [14C] BI 1356 Administered Intravenously in Healthy Male Volunteers
NCT02183610 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1 Relative Bioavailability Study of UCB0022 Tablets in Healthy Participants
NCT07220551 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants
NCT06849791 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1